Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
11/2003
11/06/2003WO2003091204A1 Phenethanolamine derivatives
11/06/2003WO2003090912A1 Pyrrolo-triazine aniline compounds useful as kinase inhibitors
11/06/2003WO2003090818A2 Drug-delivery endovascular stent and method for treating restenosis
11/06/2003WO2003090800A1 Wound dressings comprising hydrated hydrogels and enzymes
11/06/2003WO2003090766A1 Arsenic therapy for apls-type autoimmune lymph-oproliferative syndrome in mice and humans
11/06/2003WO2003090765A1 Medicinal compositions containing phtocrosslinkable chitosan derivative
11/06/2003WO2003090752A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003090751A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003WO2003090748A1 Use of compounds having ccr antagonism
11/06/2003WO2003090744A1 Antibacterial compositions comprising metal phthalocyanine analogues
11/06/2003WO2003090728A1 Use of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix
11/06/2003WO2003090714A1 Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulations
11/06/2003WO2003090708A1 External preparation for skin
11/06/2003WO2003090699A1 Cosmetic composition for promoting hair growth and/or preventing or delaying hair loss
11/06/2003WO2003090684A2 Polymer compositions containing a macrocyclic triene compound
11/06/2003WO2003090672A2 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
11/06/2003WO2003090671A2 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003WO2003090662A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
11/06/2003WO2003090640A2 Microbial cellulose wound dressing for treating chronic wounds
11/06/2003WO2003090514A2 Adipocyte complement related protein zacrp14
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003054009A3 Apoptotically active peptides
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003034900A3 Sterile, breathable patch for treating wound pain
11/06/2003WO2003032985A3 Concomitant oral and topical administration of anti - infective agents
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2003018640A3 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
11/06/2003WO2003018049A3 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
11/06/2003WO2003007905A3 Cosmetic or dermatological use of peptides for promoting adhesion between skin cells
11/06/2003WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c
11/06/2003WO2003005966A3 Topical medicine and process and apparatus for making same
11/06/2003WO2003002125A3 Combination of aminosugars and cysteine or cysteine derivatives
11/06/2003WO2002092773A3 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
11/06/2003WO2002085328A3 Method for producing an active ingredient concentrate, and an active ingredient concentrate
11/06/2003WO2002072631A3 Mhc molecule constructs and their usesfor diagnosis and therapy
11/06/2003WO2002070657A8 93870, a human g-protein coupled receptor and uses therefor
11/06/2003WO2002066649A8 ANTI-INTERFERON-α ANTIBODIES
11/06/2003WO2002051983A3 Novel compounds and compositions as cathepsin inhibitors
11/06/2003WO2002046475A3 Method of detecting and treating tuberous sclerosis complex associated disorders
11/06/2003WO2002046389A9 Genes associated with allergic hypersensitivity and mast cell activation
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002009639A3 Methods and pharmaceutical compositions for healing wounds
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030208046 Pseudo native chemical ligation
11/06/2003US20030207939 Novel 3-substituted urea derivatives and medicinal use thereof
11/06/2003US20030207937 Such as ethyl-2,2-4,4-tetramethyl-chroman-6-carboxylate; for retinoid-treatable conditions
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207902 Heterocyclic compounds useful as inhibitors of tyrosine kinases
11/06/2003US20030207893 Antihistamines such as (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone, used as antiinflammatory, antiarthritic or bronchodilator agents and/or immunology modulators
11/06/2003US20030207888 Serotonin receptor agonists such as 6-chloro-4-methyl-1,2,3,4 -tetrahydro-2,4a,5-triaza-fluorene, used for prophylaxis of nervous system, cardiovascular, gastrointestinal, eating or sleep disorders, and as antidiabetic agents
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207878 Drugs used as angiogenesis inhibitors, vascular permeability or endothelial growth factor antagonists, for prophylaxis of cancer, diabetes, psoriasis, arthritis, autoimmune diseases, inflammation or scar formation
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207864 Novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207844 Methods, compositions, and kits, are provided for the use of nitric oxide synthase inhibitors to prevent and reduce wrinkles.
11/06/2003US20030207834 The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
11/06/2003US20030207798 Hair growth promoting agent including a cyclosporin derivative as an active ingredient, and more particularly, a hair growth promoting agent including a cyclosporin A derivative substituted in the 3-position as an active ingredient.
11/06/2003US20030207446 Infectious papillomavirus pseudoviral particles
11/06/2003US20030207432 For refractory injuries, having human leukocyte elastase inhibitory activity
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207318 Kinesin-like motor protein
11/06/2003US20030207263 Method of screening therapeutic agents
11/06/2003US20030206955 Oil-in-water; nonionic and/or anionic amphiphilic lipid; anionic polymer which contains at least one hydrophobic chain; weight ratio of the amount of oily phase to the amount of amphiphilic lipid ranges from 1.2 to 10.
11/06/2003US20030206935 P-(alpha-hydroxyhydrocarbylcarbonylamino)-substituted benzoic acid esters; reducing and/or slowing down the loss of head hair and/or body hair, or inducing and/or stimulating its growth.
11/06/2003US20030206861 Uses of diterpenoid triepoxides as an antiproliferative agent
11/06/2003CA2484453A1 Medicinal compositions containing photocrosslinkable chitosan derivative
11/06/2003CA2484067A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2483530A1 Quinazoline derivatives and medicaments
11/06/2003CA2483504A1 4,4-(disubstituted)piperidine derivatives with ccr3 antagonism
11/06/2003CA2483500A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003CA2483431A1 Alternatively spliced nucleic acid molecules
11/06/2003CA2483314A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003CA2483265A1 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
11/06/2003CA2483253A1 Use of compounds having ccr antagonism
11/06/2003CA2483091A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
11/06/2003CA2483075A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003CA2483007A1 A dna enzyme to inhibit plasminogen activator inhibitor-1
11/06/2003CA2482711A1 Cosmetic composition for promoting hair growth and/or preventing or delaying hair loss
11/06/2003CA2482455A1 1,2,3,4,7,8-hexahydro-6h-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
11/06/2003CA2481324A1 [1,4]diazocino [7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents
11/06/2003CA2480497A1 Substituted pyrazine derivatives
11/06/2003CA2480291A1 Adipocyte complement related protein zacrp14
11/06/2003CA2480268A1 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003CA2480092A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/05/2003EP1359156A2 Papilloma virus vaccine
11/05/2003EP1358888A1 The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
11/05/2003EP1358883A1 Re-epithelializing pharmaceutical compositions containing xanthan gum
11/05/2003EP1358876A1 Microcapsules containing anti-acne agents
11/05/2003EP1358872A1 Use of mixtures of active compounds comprising azelaic acid and glycyrrhetic acid in the treatment of acne
11/05/2003EP1358868A2 Cosmetic composition for increasing hair growth and/or for preventing or delaying hair loss
11/05/2003EP1358857A1 The use of autologous dermal fibroblasts for the repair of skin and soft tissue defects
11/05/2003EP1358348A2 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
11/05/2003EP1358327A2 Proteins and nucleic acids encoding same
11/05/2003EP1358325A2 Protein modification and maintenance molecules
11/05/2003EP1358323A2 Regulators of apoptosis
11/05/2003EP1358316A1 Enteric nervous system derived stem and progenitor cells and uses thereof
1 ... 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 ... 1065